MX2019012476A - Composiciones y metodos para tratar la retinopatia. - Google Patents

Composiciones y metodos para tratar la retinopatia.

Info

Publication number
MX2019012476A
MX2019012476A MX2019012476A MX2019012476A MX2019012476A MX 2019012476 A MX2019012476 A MX 2019012476A MX 2019012476 A MX2019012476 A MX 2019012476A MX 2019012476 A MX2019012476 A MX 2019012476A MX 2019012476 A MX2019012476 A MX 2019012476A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating retinopathy
retinopathy
treating
Prior art date
Application number
MX2019012476A
Other languages
English (en)
Spanish (es)
Inventor
Hoffman Steven
Original Assignee
Hoffman Steven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman Steven filed Critical Hoffman Steven
Publication of MX2019012476A publication Critical patent/MX2019012476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
MX2019012476A 2017-04-21 2018-04-20 Composiciones y metodos para tratar la retinopatia. MX2019012476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762488161P 2017-04-21 2017-04-21
PCT/US2018/028552 WO2018195411A1 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Publications (1)

Publication Number Publication Date
MX2019012476A true MX2019012476A (es) 2020-02-12

Family

ID=62117055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012476A MX2019012476A (es) 2017-04-21 2018-04-20 Composiciones y metodos para tratar la retinopatia.

Country Status (11)

Country Link
US (2) US11351136B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612225A1 (cg-RX-API-DMAC7.html)
JP (1) JP7171611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190138683A (cg-RX-API-DMAC7.html)
CN (1) CN110769855A (cg-RX-API-DMAC7.html)
AU (1) AU2018254556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3060417A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992515A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012476A (cg-RX-API-DMAC7.html)
PH (1) PH12019502380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018195411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451422A1 (en) * 1990-04-13 1991-10-16 Merrell Dow Pharmaceuticals Inc. Pharmaceutically active fluoromethyltyrosine compounds
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
JP4758581B2 (ja) 1999-11-30 2011-08-31 アルコン,インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
EP2114386B9 (en) 2007-01-29 2013-09-18 Vlife Sciences Technologies Pvt Ltd. Pharmaceutical composition for treatment of diabetic complications
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JP6836991B2 (ja) 2014-12-23 2021-03-03 スティーブン・ホフマン 経皮製剤
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Also Published As

Publication number Publication date
US20180303783A1 (en) 2018-10-25
US11351136B2 (en) 2022-06-07
AU2018254556A1 (en) 2019-11-14
KR20190138683A (ko) 2019-12-13
JP7171611B2 (ja) 2022-11-15
CN110769855A (zh) 2020-02-07
US20220288003A1 (en) 2022-09-15
PH12019502380A1 (en) 2020-09-14
EP3612225A1 (en) 2020-02-26
US12364676B2 (en) 2025-07-22
CA3060417A1 (en) 2018-10-25
JP2020517663A (ja) 2020-06-18
AU2018254556B2 (en) 2024-05-02
EA201992515A1 (ru) 2020-04-09
WO2018195411A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
NZ795278A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007021A (es) Anticuerpos il-11ra.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2017005260A (es) Bifidobacterias activadas y metodos de uso de las mismas.
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
MX2019007020A (es) Anticuerpos il-11.
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
SG10201906471PA (en) Treatment of cancer with anti-lap monoclonal antibodies
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
ZA201907028B (en) Fabric care composition
HK1217490A1 (zh) 黃斑變性治療中的新穎捕獲劑
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX2019006576A (es) Metodos y materiales para usar soportes de fibrina para trasplante de epitelio de pigmento retiniano.
AU2015315168A8 (en) Targeted mutagenesis in spirulina
WO2019086646A8 (en) Feline leukemia virus vaccine
PH12017501864A1 (en) Compositions and methods for treating autism
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
AU2016361427A8 (en) Platinum anticancer agents
MX2019006551A (es) Terapia génica para mucopolisacaridosis de tipo ii.